Advanced search
Publication Cover
Acta Cardiologica Volume 73, 2018 - Issue 1
Submit an article Journal homepage
101
Views
4
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Serum paraoxonase activity in patients with ischaemic and nonischaemic dilated cardiomyopathy

Fatih GungorenDepartment of Cardiology, Faculty of Medicine, Uludag University, Bursa, Turkey; View further author information
,
Tunay SenturkDepartment of Cardiology, Faculty of Medicine, Uludag University, Bursa, Turkey; Correspondence[email protected]
View further author information
,
Alper OzturkDepartment of Cardiology, Faculty of Medicine, Uludag University, Bursa, Turkey; View further author information
,
Kerem KozDepartment of Cardiology, Faculty of Medicine, Uludag University, Bursa, Turkey; View further author information
,
Emre SarandolDepartment of Clinical Biochemistry, Faculty of Medicine, Uludag University, Bursa, Turkey; View further author information
,
Dilek YesilbursaDepartment of Cardiology, Faculty of Medicine, Uludag University, Bursa, Turkey; View further author information
,
Sumeyye GulluluDepartment of Cardiology, Faculty of Medicine, Uludag University, Bursa, Turkey; View further author information
,
Guven OzkayaDepartment of Bioistatistics, Faculty of Medicine, Uludag University, Bursa, TurkeyView further author information
&
Ali AydinlarDepartment of Cardiology, Faculty of Medicine, Uludag University, Bursa, Turkey; View further author information
 show all
Pages 85-90 | Received 11 Jan 2017, Accepted 06 Mar 2017, Published online: 12 Sep 2017

References

  • George J, Wexler D, Roth A, et al. Usefulness of anti-oxidized LDL antibody determination for assessment of clinical control in patients with heart failure. Eur J Heart Fail. 2006;8:58–62.
  • Diaz-Velez CR, Garcia-Castineiras S, Mendoza-Ramos E, et al. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J. 1996;131:146–152.
  • Cracowski JL, Tremel F, Marpeau C, et al. Increased formation of F(2)-isoprostanes in patients with severe heart failure. Heart. 2000;84:439–440.
  • Hokamaki J, Kawano H, Yoshimura M, et al. Urinary biopyrrins levels are elevated in relation to severity of heart failure. J Am Coll Cardiol. 2004;43:1880–1885.
  • McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–1847.
  • Aviram M. Atherosclerosis: cell biology and lipoproteins-inflammation and oxidative stress in atherogenesis: protective role for paraoxonases. Curr Opin Lipidol. 2012;22:243–244.
  • Draganov DI. Lactonases with organophosphatase activity: structural and evolutionary perspectives. Chem Biol Interact. 2010;187:370–372.
  • Aviram M, Rosenblat M, Bisgaier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581–1590.
  • Tang WH, Wu Y, Mann S, et al. Diminished antioxidant activity of high-density lipoprotein-associated proteins in systolic heart failure. Circ Heart Fail. 2011;4:59–64.
  • Kim JB, Hama S, Hough G, et al. Heart failure is associated with impaired anti-inflammatory and antioxidant properties of high-density lipoproteins. Am J Cardiol. 2013;112:1770–1777.
  • Karabacak M, Dogan A, Tayyar S, et al. The effects of carvedilol and nebivolol on oxidative stress status in patients with non-ischaemic heart failure. Kardiol Pol. 2015;73:201–206.
  • Cannon CP, Battler A, Brindis RG, et al. ACC clinical data standards. American College of Cardiology key data elements and definition for measuring the clinical management and outcomes of patients with acute coronary syndromes. J Am Coll Cardiol. 2001;38:2114–2130.
  • Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2008;29:270–276.
  • Levey AS, Coresh J, Greene T, Chronic Kidney Disease Epidemiology Collaboration, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254.
  • Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79–108.
  • Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
  • Eckerson HW, Wyte MC, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet. 1983;35:1126–1138.
  • Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am J Pathol. 1996;148:291–300.
  • Shekhanawar M, Shekhanawar SM, Krisnaswamy D, et al. The role of ’paraoxonase-1 activity‘ as an antioxidant in coronary artery diseases. J Clin Diagn Res. 2013;7:1284–1287.
  • Jayakumari N, Thejaseebai G. High prevalence of low serum paraoxonase-1 in subjects with coronary artery disease. J Clin Biochem Nutr. 2009;45:278–284.
  • Sentürk T, Sarandöl E, Güllülü S, et al. Association between paraoxonase 1 activity and severity of coronary artery disease in patients with acute coronary syndromes. Acta Cardiol. 2008;63:361–367.
  • Göçmen AY, Gümüşlü S, Semiz E. Association between paraoxonase-1 activity and lipid peroxidation indicator levels in people living in the Antalya region with angiographically documented coronary artery disease. Clin Cardiol. 2004;27:426–430.
  • Follath F, Cleland JG, Klein W, et al. Etiology and response to drug treatment in heart failure. J Am Coll Cardiol. 1998;32:1167–1172.
  • Asselin C, Ducharme A, Ntimbane T, et al. Circulating levels of linoleic acid and HDL-cholesterol are major determinants of 4-hydroxynonenal protein adducts in patients with heart failure. Redox Biol. 2013;2:148–155.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A worldwide pioneer in biotechnology.
Novartis. Your partner in Heart Failure & Atherosclerosis >>

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.